Peter Boyd Sells 10,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock

Key Points

• Peter Boyd, an insider at Aquestive Therapeutics, sold 10,000 shares at an average price of $6.30, reducing his stake by 3.47% and leaving him with 278,323 shares valued at approximately $1.75 million.
• Aquestive Therapeutics reported earnings of ($0.14) per share in its last quarterly results, which was better than the expected ($0.18), but its revenue of $10 million fell short of analyst estimates of $11.32 million.
• Aquestive shares have seen a recent price target increase from Oppenheimer, raising it from $7.00 to $8.00, and the stock currently holds an average rating of "Buy" from analysts, with a price target of around $10.29.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Peter Boyd sold 10,000 shares of Aquestive Therapeutics stock in a transaction on Friday, September 26th. The shares were sold at an average price of $6.30, for a total transaction of $63,000.00. Following the transaction, the insider owned 278,323 shares in the company, valued at $1,753,434.90. The trade was a 3.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded down $0.34 during midday trading on Monday, hitting $5.65. 3,783,104 shares of the company's stock traded hands, compared to its average volume of 1,807,882. The company has a market cap of $563.42 million, a PE ratio of -8.07 and a beta of 1.82. The firm's fifty day moving average price is $4.37 and its two-hundred day moving average price is $3.50. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $6.43.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently made changes to their positions in AQST. Bank of America Corp DE lifted its stake in shares of Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock worth $2,457,000 after acquiring an additional 621,614 shares during the period. Deutsche Bank AG lifted its stake in Aquestive Therapeutics by 63.9% during the fourth quarter. Deutsche Bank AG now owns 61,989 shares of the company's stock valued at $221,000 after purchasing an additional 24,170 shares during the last quarter. Millennium Management LLC lifted its stake in Aquestive Therapeutics by 111.2% during the fourth quarter. Millennium Management LLC now owns 87,227 shares of the company's stock valued at $311,000 after purchasing an additional 45,926 shares during the last quarter. ProShare Advisors LLC lifted its stake in Aquestive Therapeutics by 79.8% during the fourth quarter. ProShare Advisors LLC now owns 25,232 shares of the company's stock valued at $90,000 after purchasing an additional 11,200 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in Aquestive Therapeutics by 31.5% during the fourth quarter. Two Sigma Investments LP now owns 175,952 shares of the company's stock valued at $626,000 after purchasing an additional 42,160 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AQST has been the topic of several recent research reports. Oppenheimer lifted their target price on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an "outperform" rating in a report on Monday, September 8th. Zacks Research raised shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Finally, Lifesci Capital upgraded shares of Aquestive Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $10.29.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.